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ABSTRACT 
 In the selection leading to cancer, cancer cells make use of the normal extracellular signaling 
to gain a growth advantage over normal cells. These signals are, in part, generated by plasma 
membrane receptors. G Protein Coupled Receptors (GPCRs) and Receptor Tyrosine Kinases 
(RTKs) are major transducer of signals across the plasma membrane.  Each cell surface receptor 
family possesses unique structural characteristics and leads to specific signaling outcomes in the 
cell. However, there is extensive overlap in the signaling proteins and pathways used to produce 
these effects. Among them, β-arrestins, molecules previously considered to be associated 
exclusively with GPCRs are also involved in modulating signaling through a classical RTK, the 
insulin-like growth factor type 1 (IGF-1R). The overall objective of this thesis is to investigate 
the function and determine potential utility of the β-arrestins as molecular targets in cancer. This 
is based on the underlying hypothesis that the signaling complexes coordinated by β-arrestins 
and involving kinases and ubiquitin ligases contribute to tumorigenesis and the progression of 
cancer and could be targeted in therapies. Paper I identified the antimicrobial cathelicidin peptide 
LL-37 as a natural agonist for the IGF-1R. LL-37 binding to the receptor resulted in 
phosphorylation and ubiquitination of IGF-1R, and β-arrestin dependent signaling activation. 
This signaling activation was limited to the MAPK/ERK pathway without affecting the other 
main IGF-1R signaling pathway through PI3K/AKT, indicating that LL-37 may act as a β-
arrestin biased agonist for the IGF-1R, sustaining the invasive phenotype. Paper II investigated 
the β-arrestin-IGF-1R binding mechanism and reveal the missing links that to functionally 
portray a prototypical RTK, the IGF-1R, as a GPCR: GRK dependent phosphorylation of IGF-
1R serine residues as the underlying mechanism for β-arrestin binding. While highlighting the 
cross-talk between the IGF-1R and GPCR at the level of GRKs, this study identified the 
molecular basis of IGF-1R biased signaling to be dependent on β-arrestin/IGF-1R interaction 
controlled by GRKs. Paper III investigates the paradox of agonist-like IGF-1R downregulation 
following treatment with antagonist anti-IGF-1R antibodies. The results show that this process is 
governed by β-arrestin1 recruitment to the IGF-1R, initiating receptor ubiquitination and 
degradation. Yet, this β-arrestin1 recruitment to the IGF-1R initiates a wave of ERK signaling 
activation, demonstrated to have a protective role for the cancer cells. Paper IV reveals that 
β-arrestin1 mediated IGF-1R signalling is crucial for H-Ras induced transformation.  The 
mechanism underlying this process is impaired intensity and spatial distribution of activated 
MAPK/ERK signalling in the absence of β-arrestin1. 
 
     In conclusion, this thesis demonstrates that β-arrestins play a central role in IGF-1R function, 
controlling ubiquitination/degradation of the receptor, and receptor signaling. This study, 
focusing on β-arrestins as central molecules in modulation of the intracellular signaling, may 
provide new clues in the search for new molecular-designed treatments of cancer.  
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